Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme succinylarginine dihydrolase in mice. by Ishibashi Daisuke et al.
 1 
Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme 




















Department of Molecular Microbiology and Immunology, Nagasaki University Graduate 
School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan  
b
Division of Molecular Neurobiology, The Institute for Enzyme Research, The University of 
Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan 
 
Running title: Antigenic mimicry-mediated prion vaccine 
 
*Corresponding author at Division of Molecular Neurobiology, The Institute for Enzyme 
Research, The University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan 
Tel.: +81 88 633 7438; Fax: +81 88 633 7440. 
E-mail: sakaguch@ier.tokushima-u.ac.jp 
 
Keywords: prion, vaccine, antigenic mimicry, humoral immunity 
 2 
Abstract 
Prions, the causative agents of prion diseases, are immunologically tolerated because their 
major component, prion protein (PrP), is a host-encoded molecule. Therefore, no effective 
prion vaccines have been developed. We previously showed that heterologous bovine and 
sheep PrP immunizations of mice overcame tolerance by an antigenic mimicry mechanism to 
efficiently induce anti-PrP auto-antibodies (Abs), significantly prolonging incubation times in 
mice subsequently infected with the mouse-adapted Fukuoka-1 prion. These results prompted 
us to investigate if non-mammal derived molecules able to antigenically mimic anti-prion 
epitopes, could act as prion vaccines. We show here that immunization of mice with 
recombinant succinylarginine dihydrolase, a bacterial enzyme with a peptide sequence similar 
to an anti-prion epitope, induced anti-PrP auto-Abs with anti-prion activity and significantly 
retarded survival times of the mice subsequently infected with Fukuoka-1 prions. These 
results might open a way for development of a new type of antigenic mimicry-based prion 




Prion diseases, which include Creutzfeldt-Jakob disease (CJD) in humans and bovine 
spongiform encephalopathy (BSE) and scrapie in animals, are neurodegenerative disorders 
caused by prions [1, 2]. It is believed that BSE prions have been orally transmitted to humans 
via contaminated foods, causing a new variant type of CJD (vCJD) [3, 4]. Fortunately, BSE 
incidence has been dramatically decreased, mainly due to the ban on using meat and bone 
meal ingredients in animal feed, thereby reducing the risk of BSE transmission to humans. In 
contrast, 4 vCJD cases were reported among recipients transfused with blood from donors 
who eventually developed vCJD [5-7], suggesting an increasing risk of secondary 
transmission of vCJD among human populations via medical treatments and/or procedures. 
However, no prophylactic vaccines against prion diseases have been developed. 
Prions are mainly composed of the proteinase K (PK)-resistant prion protein, 
designated PrP
Sc
, which is produced by conformational conversion of the normal cellular 
isoform, PrP
C
, a glycosylphosphatidylinositol-anchored membrane glycoprotein abundantly 
expressed in neurons [1, 2]. Thus, PrP is a potential candidate molecule for prion vaccines. 
Indeed, mice transgenically expressing 6H4 anti-PrP monoclonal antibody (mAb) developed 
the disease with very prolonged onset after intraperitoneal infection with mouse-adapted 
scrapie RML prions [8]. Moreover, passive immunization with anti-PrP mAbs, ICSM 18 and 
35, markedly attenuated the disease in mice intraperitoneally infected with RML prions [9]. 
However, PrP is a host-encoded protein. Therefore, PrP vaccines might cause autoimmune 
reactions in an immunized host. In addition, PrP vaccines have another possible adverse effect 
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as immunized PrPs might be converted into infectious PrPs or prions. Indeed, it was recently 
reported that recombinant mouse PrP (rMoPrP) mixed with RNAs and lipids, both of which 
are ubiquitous molecules in vivo, was converted into infectious PrP or a prion in vitro after 
being subjected to protein misfolding cyclic amplification (PMCA) [10]. These indicate that, 
molecules other than PrP, may be useful as prion vaccines. 
We previously demonstrated that heterologous PrPs function as antigen mimicking 
molecules to host PrP [11]. Heterologous recombinant bovine and sheep PrPs were highly 
immunogenic in mice, efficiently inducing anti-PrP auto-Abs, and immunization with these 
proteins significantly prolonged incubation times in mice inoculated with the mouse-adapted 
Fukuoka-1 prion [11]. This therefore suggested that certain molecules, if able to antigenically 
mimic anti-prion epitopes, could behave as prion vaccines.  
The aim of this study is to investigate this possibility. We show here that 
immunization of mice with recombinant succinylarginine dihydrolase (SADH), a bacterial 
molecule with a sequence similar to the 6H4 anti-prion epitope, elicited Abs not only to itself 
but also crossreactive Abs to the 6H4 epitope of PrP. We also show that the anti-SADH sera 
possessed anti-prion activity, reducing PrP
Sc
 levels in prion-infected cells, and that 
immunization of the recombinant protein significantly retarded survival times of mice 
infected with Fukuoka-1 prions. These results suggest that antigenic mimicry-based prion 




2. Materials and methods 
2.1. Animals 
4-week old female BALB/c mice were purchased from SLC Japan, Shizuoka, Japan. Mice 
were cared for in accordance with the Guidelines for Animal Experimentation of Nagasaki 
University. 
 
2.2. Expression and purification of recombinant proteins 
A DNA fragment corresponding to residues 297-447 of SADH (GenBank accession No. 
U00096) of DH5Escherichia coli was amplified by polymerase chain reaction (PCR) using 
a sense primer (3’-ccggatccgtatggggttatctcaatga-5’; underlined sequence, BamH I site) and an 
anti-sense primer (3’-gggtcgactccattgccccctccctcgcg-5’; underlined sequence, Sal I site). A 
DNA fragment encoding residues 331-447 of SADH of Salmonella enterica subspecies 
enterica serovar Paratyphi A str. ATCC 9150 (GenBank accession No. NC006511) was also 
amplified by PCR using a sense primer (3’-cggatcctcagatgctgtggcgcccta-5’; underlined 
sequence, BamH I site) and an anti-sense primer (3’-gggtcgactccatcagccgcccccgtttgct-5’; 
underlined sequence, Sal I site). Following sequence confirmation of the PCR products, the 
fragments were digested with BamH I and Sal I and inserted into a pQE30 vector (QIAGEN, 
Hilden, Germany) and the vector developed to produce the protein of interest with an 
N-terminal 6His tag. E.coli(M15) cells were freshly transformed by the plasmids, cultured in 
LB medium containing 1 mM isopropylthio--D-galactoside (IPTG), and collected by 
centrifugation. The collected cells were lysed using CelLytic B Bacterial Cell Lysis/Extraction 
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Reagent (Sigma-Aldrich Co. St Louis, USA) in the presence of deoxyribonuclease I and the 
lysate was centrifuged at 25,000g for 10 min. The resulting pellet containing SADH protein 
was suspended in Reagent containing 0.2 mg/ml lysozyme and incubated with occasional 
shaking at room temperature (RT) for 15 min. Volume of the suspension was then increased 
by addition of 1:10 diluted Reagent and centrifuged at 25,000g for 10 min. The resulting 
pellet was washed 3 times with 1:10 diluted Reagent, suspended in lysis buffer (8 M Urea, 10 
mM Tris-HCl, 100 mM Na2HPO4, pH 8.0) and SADH recombinant proteins were purified 
using a Ni-NTA column in denaturing conditions as recommended in the manufacturer’s 
protocol.  
Recombinant mouse PrP (rMoPrP) without a 6His tag was expressed and purified 
as described elsewhere [11]. In brief, a DNA fragment corresponding to MoPrP 23-231 was 
amplified by PCR. Following sequence confirmation, this fragment was digested with Nde I 
and BamH I and inserted into a pET11a vector (Novagen, Inc., WI, USA). E. coli (BL21) cells 
were transformed and cultured in LB medium. rMoPrP was purified by subjecting the extract 




Purified recombinant proteins were dialyzed against PBS. 100 g of the dialyzed protein was 
intraperitoneally inoculated into a 4-week old female BALB/c mouse (SLC Japan) together 
with complete Freund’s adjuvant (CFA; Difco Laboratories, Detroit, MI) for the first 
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immunization. Additional immunizations were performed by intraperitoneal inoculation of the 
same amounts of the protein with incomplete Freund’s adjuvant (Difco Laboratories) into the 
mice at 2-week intervals. Antisera were collected one week after the final immunization and 
stored at -20ºC until used. 
 
2.4. Enzyme-linked immunosorbent assay (ELISA)  
For detection of purified SADH recombinant proteins or rMoPrP without a 6His tag, each 
well of a 96 well immunoplate (Nunc, Roskilde, Denmark) was coated with 500 ng of the 
proteins by overnight incubation at 4 ºC and then blocked with PBS containing 0.05% 
Tween-20 (T-PBS) and 25% Blocking One (Nakarai tesque Co., Kyoto, Japan) at 37ºC for 1 
hr. To detect specific IgG Abs, serially 10-fold diluted antiserum was added to the wells for 1 
hr at 37ºC and unbound Abs were removed by washing twice with T-PBS. Immune complexes 
were detected using secondary goat anti-mouse IgG Abs conjugated with HRP (GE 
Healthcare, Buckinghamshire, England), 2 mM 
2,2’-Azino-bis(3-Ethylbenzthiazoline-6-sulfonic acid), and 0.04% H2O2. Antibody titers were 
determined using colorimetric values expressed at 405 nm.  
For detection of a MoPrP peptide 131-154 (>70% purity, Sigma-Aldrich Japan K. 
K., Hokkaido, Japan), we used a more sensitive ELISA system. 1 g of the peptide was 
coated on a 96 well immunoplate (Nunc) and similarly subjected to the procedures described 
above except that the immunocomplexes were detected using 3,3’,5,5’-tetramentylbenzidine 
(Pierce, Rockford, IL) at 450 nm.  
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2.5. Fluorescence-activated cell sorter (FACS) analysis 
PrP
C
-deficient hippocampal neurons, designated HpL3-4 [12], and HpL3-4 cells 
overexpressing exogenous PrP
C
, designated HpL3-4TR [12] (kindly provided by Prof. 
Onodera, The University of Tokyo, Japan), were harvested in PBS containing 20 mM EDTA. 
Cells were then suspended in BSS buffer (140 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 0.3 
mM Na2HPO4, 0.4 mM KH2PO4, 1 mM CaCl2) containing 5% fetal bovine serum (FBS), and 
incubated with 100-fold diluted antisera for 1 hr on ice. The treated cells were then washed 3 
times with BSS buffer containing 5% FBS, reacted with Alexa Fluor® 546 goat anti-mouse 
IgG (Invitrogen, Carlsbad, CA) and analyzed using a flow cytometer (BD FACSCanto II 
Flow Cytometer, BD Biosciences, San Jose, CA).  
 
2.6. Western blotting analysis 
Total proteins of cell lysates treated with or without 20 g/ml of proteinase K (PK) 
(Sigma-Aldrich Co.) at 37°C for 30min were separated on 15% SDS-PAGE and electrically 
transferred onto a PVDF membrane (Millipore, MA, USA). The PK activity was blocked by 
boiling in a buffer (50 mM Tris-HCl, pH 6.8, 5% glycerol, 1.6% SDS, 100 mM dithiothreitol) 
for 5 min. The membrane was immersed in TBST (0.1% Tween 20, 100 mM NaCl, 10 mM 
Tris-HCl, pH 7.6) containing 5% nonfat dry milk and then incubated either with 
1:5000-diluted M-20 anti-PrP goat polyclonal Ab (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA) to detect PrP or with 1:5000-diluted Ab against -actin (Sigma-Aldrich Co.). Immune 
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complexes were visualized using secondary sheep anti-mouse IgG Abs conjugated with HRP 
(GE Healthcare) and the ECL system (GE Healthcare). 
 
2.7. In vitro assay of anti-prion activity of anti-sera 
The in vitro anti-prion activity of antisera was assessed by their activities to reduce PrP
Sc
 
levels in mouse neuroblastoma N2a cell line persistently infected with a mouse-adapted 
Fukuoka-1 prion, termed N2a58-Fk [13]. The cells were cultured in DMEM containing 10% 
FBS. 2  10
5 
cells in one well of a 6 well plate were incubated with 1:10 or 1:50-diluted 
antisera for 2 days. The cells were then lysed in a lysis buffer (1% TritonX-100, 1% sodium 
deoxycholate, 300 mM NaCl, 100 mM Tris-HCl, pH 7.5) and the lysates were subjected to 
Western blotting.  
 
2.8. Prion inoculation 
Brains were removed from diseased mice infected with the mouse-adapted Fukuoka-1 prion 
[14] and then homogenized to 1% (w/v) in PBS. Aliquots (100 l) of the homogenate were 
intraperitoneally inoculated into each mouse 1 week after receiving 5 immunizations.  
 
2.9. Cell viability assay 
Cell viability was determined by usingthe PreMix WST-1 Cell Proliferation Assay System 
(Takara Bio Inc., Shiga, Japan). N2a58 cells were plated on 96-well plates at a density of 5 × 
10
3
 cells/well in 100 l of Dulbecco’s Modified Eagle Medium (DMEM) containing 10% 
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FBS. On the next day, each of the antisera was added into the culture medium at the final 
concentration of 10%. After 48 hr, the WST-1 assay was performed according to the 
manufacturer's instructions. In brief, the cells treated with antisera were incubated with 




The brain tissues of mice were fixed in 4% paraformaldehyde and sectioned into 5-m-thick 
sections after paraffin embedding. The tissue sections were stained with hematoxylin and 
eosin (HE).  
 
2.11. Statistical analysis 
Logrank test was used for analysis of the survival times of mice. Colorimetric data from 





3.1. Bacterial enzyme SADH has an amino acid sequence similar to 6H4 anti-prion epitope 
We selected the 6H4 anti-prion epitope, which corresponds to residues 144-152 of MoPrP 
[15] (Fig. 1A), as a target sequence because this epitope overlaps the ICSN18 anti-prion 
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epitope (residues 146-159) [9], and both 6H4 and ICSN18 mAbs have already been 
demonstrated to be effective against prions in mice [8, 9]. We then searched for 
non-mammal-derived molecules with sequences similar to the epitope using Basic Local 
Alignment Search Tool in the National Center for Biotechnology Information website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). As a result, we found a 6H4-mimicking sequence in 
the bacterial enzyme SADH (Fig. 1A). SADH is a much conserved molecule involved in the 
arginine succinyltransferase pathway in Escherichia coli and related bacteria including 
Salmonella enterica subspecies, Klebsiella aerogenes and Pseudomonas aeruginosa [16].  
 
3.2. SADHs elicit marked Ab responses in mice 
To investigate whether or not SADH proteins could be immunogenic in mice, we first 
recombinantly expressed and purified the recombinant SADH protein from Escherichia coli 
[hereafter referred to as SADH(E)] or Salmonella enterica subspecies enterica serovar 
Paratyphi A strain [hereafter referred to as SADH(S)] (Fig. 1B). The recombinant proteins 
were designed to have the mimicking sequence at the center and a 6xHis sequence at the 
N-terminus. The SADH(S) recombinant protein was higher than SADH(E) in molecular 
weight because of an additional 35 amino acids in the N-terminal region. The purified 
recombinant proteins were then intraperitoneally inoculated into BALB/c mice 5 times at 
2-week intervals. We collected antisera from the mice 1 week after the final immunization 
and subjected them to an ELISA to detect specific IgG responses against the respective 
immunogens. No increase in optical density values at 405 nm (OD405) was observed against 
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SADH(E) and SADH(S) immunogens with control sera from non-immunized mice (Fig. 1C). 
In contrast, anti-SADH(E) and anti-SADH(S) sera from each of the immunized mice showed 
very high OD405 values against the respective immunogens (Fig. 1C). These results indicate 
that SADH(E) and SADH(S) recombinant proteins are highly immunogenic in mice, inducing 
very high Ab responses.  
 
3.3. SADHs induce anti-PrP auto-Abs in mice 
We then investigated whether or not SADH proteins could induce anti-PrP auto-Abs in mice. 
Since the immunizing recombinant proteins contained a 6xHis tag, we used untagged rMoPrP 
as an ELISA antigen to eliminate reactivity against the tag with crossreacting Abs that might 
be produced in the immunized mice. Compared to non-immunized sera, significantly higher 
OD405 values were detected with anti-SADH(E) and anti-SADH(S) sera (Fig. 2A). These 
results indicate that immunization with SADHs could induce anti-PrP auto-Abs in mice. We 
also investigated whether the antisera could recognize native PrP or PrP
C
 expressed on the 
cell surface using FACS analysis. HpL3-4 cells are devoid of PrP
C
 while HpL3-4TR cells 
express abundant PrP
C
 on their surface. Non-immunized sera induced no signal shift of 
HpL3-4TR cells, compared to the signal of HpL3-4 cells (Fig. 2B, left panel). In contrast, the 
signal of HpL3-4TR cells was slightly but distinctly shifted to the right by the anti-SADH(S) 
(Fig. 2B, middle panel) and anti-SADH(E) sera(Fig. 2B, right panel), indicating that the 
anti-SADH sera recognize PrP
C
 expressed on the cell surface. 
 
 13 
3.4. Anti-SADH sera recognize the 6H4 anti-prion epitope 
SADH(E) and SADH(S) recombinant proteins have an amino acid sequence similar to the 
6H4 anti-prion epitope. We therefore investigated if anti-SADH(E) and anti-SADH(S) sera 
could react with the epitope using an ELISA with a PrP peptide 131–154, which encompasses 
the 6H4 epitope. We used a more sensitive ELISA for detecting the peptide because the 
conventional ELISA used for detection of full-length rMoPrP was less sensitive to detecting 
the specific signals of the peptide [11]. This sensitive ELISA resulted in higher backgrounds 
from non-immunized sera (Fig. 2C). However, the 20-fold diluted anti-SADH(E) and 
anti-SADH(S) sera showed significantly higher OD450 values, compared to control 
non-immunized sera (Fig. 2C), indicating that SADH(E) and SADH(S) recombinant proteins 
induce anti-PrP auto-Abs reacting with the 6H4 anti-prion epitope in mice. 
 
3.5. Anti-SADH sera decrease PrP
Sc
 levels in a prion-infected cell line 
We also investigated if anti-SADH sera could have anti-prion activities. Mouse 
neuroblastoma N2a cell line persistently infected with Fukuoka-1 prions, termed N2a58-Fk, 
was incubated for 2 days with 10 or 50-fold diluted anti-sera and thereafter subjected to 
Western blotting with M-20 anti-PrP Ab, which recognizes the C-terminal part of PrP. 
Anti-SADH(E) or anti-SADH(S) sera taken from two immunized mice reduced PrP
Sc
 levels in 
the cells in a dose-dependent manner, compared to the PrP
Sc
 levels in the cells treated with 
non-immunized sera (Fig. 3A). Total PrP levels in N2a58-Fk and PrP
C
 levels in uninfected 
parental N2a58 cells were not affected by the treatment with these antisera (Fig. 3A and B). 
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No cytotoxicity was detected with these antisera in N2a58 cells (Fig. 3C). These results 
indicate that immunization with SADH(E) and SADH(S) recombinant proteins induce 
anti-prion Abs in mice, and that anti-SADH(E) or anti-SADH(S) sera are effective against 
prions in N2a58-Fk cells without affecting the PrP
C
 levels.  
 
3.6. Effects of immunization with SADH recombinant proteins against mouse-adapted 
prion in mice 
We investigated the effects of the immunization with SADH recombinant proteins against 
prions. BALB/c mice were intraperitoneally immunized with purified recombinant SADH(E) 
and SADH(S) proteins 5 times at 2-week intervals and thereafter intraperitoneally inoculated 
with Fukuoka-1 prion 1 week after the final immunization. Non-immunized mice eventually 
died of the disease 29828 days post-inoculation (p.i.) (Table 1). However, mice immunized 
with SADH(E) and SADH(S) recombinant proteins displayed significantly longer survival 
times at 32915 (p=0.0284) and 32121 days p.i. (p=0.0384), respectively (Table 1). HE 
staining of the brains of terminally ill mice either immunized with the recombinant proteins or 
non-immunized revealed indistinguishably abundant vacuoles throughout the brains, 
particularly in the cortex, the thalamus and the cerebellar white matter (Fig.4). Hippocampal 
neurons seemed undamaged in the immunized mice, compared to those in non-immunized 
control mice (Fig. 4). No lymphocyte infiltration was detected in the brains of the immunized 
and non-immunized mice by immunohistochemistry using anti-T cell Abs, including 
anti-CD4 and anti-CD8 Abs, and an anti-B cell Ab, such as anti-CD45R Ab (data not shown). 
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These results indicate that immunization with SADH(E) and SADH(S) recombinant proteins 




In the present study, we showed that the bacterial enzymes SADH(E) and SADH(S), which 
carry a peptide sequence mimicking the 6H4 anti-prion epitope, are highly immunogenic in 
mice, eliciting Ab responses against not only themselves but also the 6H4 epitope. We also 
showed that anti-SADH(E) and anti-SADH(S) sera were able to prevent PrP
Sc
 formation in 
N2a cells that were persistently infected with Fukuoka-1 prion, and that immunization with 
the recombinant proteins significantly prolonged survival times in mice subsequently infected 
with Fukuoka-1 prion. These results indicate that the 6H4 mimicking sequence in SADH(E) 
and SADH(S) recombinant proteins was immunogenic in mice, eliciting anti-prion Abs that 
recognize the 6H4 epitope and thereby exerting anti-prion activities.  
We previously showed that immunization of CFA with rMoPrP into BALB/c mice 
with the same regimen as we employed in this study had no effects on the survival times of 
the mice intraperitoneally infected with Fukuoka-1 prion [11]. In contrast, the same 
immunization using CFA with heterologous bovine or sheep rPrP significantly extended the 
survival times of the immunized mice [11]. rMoPrP was immunologically tolerated in 
BALB/c mice while bovine and sheep rPrPs were highly immunogenic in BALB/c mice, 
inducing anti-PrP auto-Abs [11]. These results clearly indicate that the anti-prion effects in 
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BALB/c mice immunized with SADH(E) and SADH(S) recombinant proteins are due to the 
immunization of the recombinant proteins, not due to the CFA. 
 The exact mechanism for the protective effects of the immunization with SADH(E) 
and SADH(S) recombinant proteins against the prion infection remains unknown. The 
peripherally inoculated prions first accumulate in the peripheral lymphoreticular tissues, such 
as spleen and lymph nodes, before invading the central nervous system. White et al. showed 
that passive immunization of anti-PrP mAbs, ICSM 18 and 35, into the peritoneal cavity 
markedly reduced accumulation of PrP
Sc
 and infectivity in the spleen of mice intraperitoneally 
infected with RML prions and attenuated the disease in these mice [9]. However, the same 
administration of these mAbs showed no effect on the disease in the mice already developing 
clinical symptoms or intracerebrally infected with the prions [9]. This is probably because 
Abs are unable to efficiently infiltrate the brain across the blood-brain barrier. These results 
indicate that substantial suppression of peripheral prion replication early in the incubation 
period could be protective against prion diseases. However, at present, we do not know 
whether immunization with SADH(E) and SADH(S) recombinant proteins would be effective 
against the peripheral prion replication.  
 Significantly higher OD450 values were obtained by ELISA with anti-SADH sera 
against peptide 131-154, which encompasses the 6H4 epitope, clearly indicating that the 
immunization with SADH(E) and SADH(S) recombinant proteins elicited Abs reactive with 
the 6H4 epitope in mice. Instead of the conventional ELISA used for detection of full-length 
rMoPrP, we used a more sensitive ELISA for detecting peptide 131-154. This is because we 
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anti-SADH(E) (n=2) and anti-SADH(S) sera (n=2) and then subjected to a cell viability assay. 
No significant reduction in the cell viability was detected in these cells. 
 
Fig. 4. HE staining of the brains of terminally ill mice with or without SADH recombinant 
protein immunization. No disease-specific vacuoles were observed in the brains of uninfected 
mice. In contrast, terminally ill mice either immunized with the recombinant proteins or not, 




PrP vaccines may risk causing adverse effects in the immunized host. First, it was 
shown that certain anti-PrP mAbs against residues 95-105 or the octapeptide repeat region 
were neurotoxic in mice, causing neuronal cell death [21, 22]. Thus, PrP vaccines might 
induce such neurotoxic anti-PrP Abs in the immunized host. Second, since PrP is a host 
protein, PrP vaccines might cause autoimmune responses in the immunized host. Third, 
importantly, it was reported that rMoPrP was converted into infectious PrP in vitro by 
incubating with ubiquitous molecules, RNAs and lipids, and being subjected to PMCA [10]. 
Thus, PrP vaccines might have the possibility that immunizing PrP molecules are converted 
into infectious PrPs or prions in the immunized host. Considering these potential risks, PrP 
vaccines might be unfavorable as prion vaccines.  
SADH(E) and SADH(S) contain a sequence mimicking the 6H4 epitope, but their 
overall amino acid sequences are quite different from PrPs. Therefore, unlike PrPs, SADH(E) 
and SADH(S) have no potential to be converted into an infectious molecule. No autoimmune 
responses were also reported in mice transgenically expressing 6H4 mAb [15]. PrP
C
 is most 
abundantly expressed in the brain. However, we detected no lymphocyte infiltration in the 
brains of terminally ill mice immunized with the recombinant proteins on 
immunohistochemical analysis. Moreover, no neurotoxic effects were shown with 6H4 mAb 
in mice [15]. Indeed, on inspection, we did not detect any abnormal behaviors in mice 
immunized with SADH(E) and SADH(S) recombinant proteins, compared to non-immunized 
mice. Hippocampal neurons were shown to be very vulnerable to the toxicity of 4H11 
anti-PrP antibody in mice [21, 22]. However, we observed no significant loss of hippocampal 
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neurons in terminally ill mice immunized with SADH(E) and SADH(S) recombinant proteins. 
Taken together, these indicate that SADH(E) and SADH(S) recombinant proteins as antigens 
lack the adverse effects that might be potentially induced by PrP vaccines. Therefore, our 
present results suggest that, rather than PrP molecules, SADH(E) and SADH(S) or other 
non-mammal derived molecules carrying an amino acid sequence(s) antigenically mimicking 
the anti-prion epitopes could be candidate molecules for study as prion vaccines.  
However, immunization with SADH(E) and SADH(S) recombinant proteins 
displayed significant but slight effects against Fukuoka-1 prions in mice. The increase in 
incubation times for the disease closely correlates with the titers of anti-PrP auto-Abs 
produced in immunized mice [17, 23]. Sigurdsson et al. showed that mice producing higher 
titers of anti-PrP auto-Abs in plasma after subcutaneous immunization with mouse 
recombinant PrP developed the disease with longer incubation times after intraperitoneal 
infection with 139A prions. It was also reported that the protective effects of oral 
immunization with a mouse PrP-expressing attenuated Salmonella typhimurium LVR01 LPS 
vaccine strain against oral prion infection were nicely correlated to the titers of anti-PrP IgG 
and IgA auto-Abs produced in the immunized mice [23]. It is thus suggested that the modest 
effects of the immunization with SADH(E) and SADH(S) recombinant proteins against 
Fukuoka-1 prions might be attributable to low titers of the anti-PrP auto-Abs produced in the 
immunized mice. Indeed, anti-SADH(E) and anti-SADH(S) sera showed very low OD405 
values against rMoPrP on the ELISA, compared to those against recombinant SADH(E) and 
SADH(S) proteins. Thus, further studies are required to enhance the antigenicity of the mimic 
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sequence in SADH(E) and SADH(S) recombinant protein to induce much higher titers of 
anti-prion Abs, enough to effectively prevent prion infection. Furthermore, it might be 
interesting to search for other non-mammalian molecules carrying an anti-prion 
epitope-mimic sequence(s) with higher antigenic properties. SADH is a very conserved 
molecule in Escherichia coli, Salmonella enterica subspecies, Klebsiella aerogenes and 
Pseudomonas aeruginosa [16]. Therefore, it might be of interest to investigate whether or not 




We show here that immunization with the bacterial molecules SADH(E) and SADH(S), which 
carry a sequence similar to the 6H4 anti-prion epitope, elicited anti-prion Abs in mice and 
significantly retarded survival times of the mice infected with Fukuoka-1 prions. This 
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Fig. 1. High immunogenicity of the bacterial enzyme SADHs carrying a sequence mimicking 
the 6H4 anti-prion epitope in mice. (A) Comparison of the amino acid sequence of the 6H4 
anti-prion epitope to the mimic sequences of SADH(E) and SADH(S). Arabic numbers 
represent the codon number of each indicated amino acid in each molecule. (B) Coomassie 
brilliant blue staining of purified SADH(E) and SADH(S) recombinant proteins. (C) The 
OD405 values of anti-SADH(E) and anti-SADH(S) sera against the respective antigens 
evaluated by an ELISA. Purified recombinant protein was intraperitoneally inoculated into 
BALB/c mice 5 times at 2-week intervals and anti-sera were taken 1 week after the final 
immunization. Compared to control sera from non-immunized mice (n=6), anti-SADH(E) 
(n=21) and anti-SADH(S) sera (n=20) showed very high OD405 values against the respective 
immunogens. 
 
Fig. 2. SADH recombinant proteins induce anti-PrP auto-Abs able to recognize the 6H4 
anti-prion epitope. (A) Anti-SADH(E) and anti-SADH(S) sera recognize full-length rMoPrP. 
Anti-SADH(E) (n=10) and anti-SADH(S) sera (n=9) were diluted 1:20 and subjected to an 
ELISA against purified rMoPrP without a 6 x His tag. Higher OD405 values were detected 
with anti-SADH(E) and anti-SADH(S) sera than those of control sera (n=9) from 
non-immunized mice. (B) Anti-SADH(E) and anti-SADH(S) sera recognize PrP
C
 on the cell 




on the HpL3-4TR cells was detected by the anti-SADH(E) (middle panel) and anti-SADH(S) 
sera (right panel) but not by non-immunized sera (left panel). (C) Anti-SADH(E) (n=16) and 
anti-SADH(S) sera (n=15) recognize the 6H4 anti-prion epitope. To investigate 
anti-SADH(E) and anti-SADH(S) sera for their binding activity to a 6H4 epitope-containing 
PrP peptide, we employed a more sensitive ELISA as described in Materials and Methods. 
Anti-SADH(E) and anti-SADH(S) sera were diluted at 1:20 and subjected to the ELISA using 
the PrP peptide 131–154 encompassing the 6H4 epitope as an antigen. This sensitive ELISA 
resulted in higher backgrounds. However, significantly higher OD450 values were detected 
with anti-SADH(E) and anti-SADH(S) sera, compared to those with control non-immunized 
sera (n=6). *p < 0.05; **p < 0.01. 
 
Fig. 3. In vitro anti-prion activity of anti-SADH(E) and anti-SADH(S) sera. (A) 
Anti-SADH(E) and anti-SADH(S) sera reduce PrP
Sc
 levels in prion-infected cells. N2a58-Fk 
cells were incubated for 2 days with anti-SADH(E) (n=2) and anti-SADH(S) sera (n=2) at 
indicated dilutions and then subjected to Western blotting. Compared to non-immunized sera, 
anti-SADH(E) or anti-SADH(S) sera reduced PrP
Sc
 levels in the cells in a dose-dependent 
manner without affecting the level of total PrP. (B) Anti-SADH(E) and anti-SADH(S) sera do 
not reduce PrP
C
 levels in uninfected cells. N2a58 cells were similarly incubated with 
anti-SADH(E) (n=2) and anti-SADH(S) sera (n=2). No significant reduction in the PrP
C
 level 
was detected in these cells. (C) Anti-SADH(E) and anti-SADH(S) sera are not cytotoxic. 
N2a58 cells were similarly incubated without (-) or with non-immunized (n=2), 
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anti-SADH(E) (n=2) and anti-SADH(S) sera (n=2) and then subjected to a cell viability assay. 
No significant reduction in the cell viability was detected in these cells. 
 
Fig. 4. HE staining of the brains of terminally ill mice with or without SADH recombinant 
protein immunization. No disease-specific vacuoles were observed in the brains of uninfected 
mice. In contrast, terminally ill mice either immunized with the recombinant proteins or not, 




Table 1. Prophylactic effects of immunization with SADHs on prion infection. 
Immunogen 
Survival times 
(Mean  SD, days) 




- 298  28 10/10  
SADH(E) 329  15 5/5 0.0284 
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